SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently at the center of intense market speculation and short-seller conflict as investors react to favorable comparative clinical data against major competitors in the bladder cancer space. The community is focused on the strategic impact of securing a reliable BCG supply chain, the potential for label expansion, and the belief that the stock is being heavily manipulated ahead of pending regulatory milestones.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant community traction as investors anticipate the imminent 80th event trigger for its REGAL Phase 3 clinical trial in acute myeloid leukemia, which is viewed as a pivotal catalyst for the company's valuation. Market participants are actively debating the potential for GPS to deliver curative outcomes, with many highlighting institutional accumulation and management's recent optimistic commentary on the trial's survival data as key drivers behind the bullish sentiment.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are maintaining a cautious but speculative stance on NVDA as the market awaits earnings, with the community actively debating whether the stock will break higher or succumb to a "sell the news" correction. The primary focus for traders is the potential for significant market-wide volatility, as participants attempt to gauge demand for AI infrastructure and data-center revenue while hedging against broader macroeconomic uncertainties.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as shares surge following a strong earnings report that topped expectations for both revenue and profit, driven by robust store expansion and resilient restaurant traffic. Investors are actively debating the company's premium valuation and rapid growth strategy, with many community members highlighting the strength of its expansion model compared to other fast-casual peers.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is currently facing intense volatility as the community reacts to a high-stakes trade summit in China, where expectations for a massive jet order have collided with conflicting reports on the actual deal size. Investors remain deeply divided, debating whether the stock is a long-term industrial turnaround opportunity with a massive backlog or a victim of persistent market manipulation and geopolitical headwinds.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing sustained downward pressure as investors grow increasingly cautious following leadership changes and a weaker-than-expected outlook, leading the stock to trade near 52-week lows. While many community members remain optimistic about the company's subscription-based model and long-term potential, others are actively debating whether to average down their positions or exit entirely given the consistent price decline and market volatility.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is trending as investors digest a strong earnings beat and raised full-year guidance that highlights robust demand across AI infrastructure, aerospace, and defense. The community remains actively focused on whether this performance signals a long-term structural uptrend or a temporary order cycle, with many traders discussing potential breakout levels and the stock's role in the broader AI supply chain.

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Monopar Therapeutics Inc

Monopar Therapeutics is trending as investors react to the company's recent publication of positive Phase 2 study results, which demonstrate that its candidate, ALXN1840, effectively improves copper balance in Wilson disease patients. The community is actively discussing the drug's regulatory progress toward a planned NDA filing, while analysts continue to adjust their outlooks based on this potential de-risking of the company's clinical pipeline.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending due to persistent acquisition rumors and its role as a key player in the evolving AI security landscape, with investors closely watching its partnerships with major tech firms. The community is actively debating the stock's significant undervaluation compared to its cybersecurity peers while weighing concerns over insider selling and market-wide volatility.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as market participants engage in heated debates over the impact of geopolitical conflicts, energy market volatility, and the broader implications of U.S. domestic policy, leading some investors to double down on a long-term 'buy and hold' strategy. Community discussion remains polarized, focusing on how these ongoing economic uncertainties and political shifts continue to influence portfolio allocations and investor sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This...

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money Wall Street's Cardiac Bet: Where Diagnostics Meet the Money PR Newswire VANCOUVER, BC, May 12, 2026 ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ --Cardiovascular...

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active...

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026. The company will take part in a...

Bokf Na Reduces Stock Position in Bristol Myers Squibb Company $BMY

Bokf Na lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange...

Bristol Myers Squibb Company $BMY Shares Sold by RNC Capital Management LLC

RNC Capital Management LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and...

Bristol Myers Squibb Company $BMY Shares Bought by Intact Investment Management Inc.

Intact Investment Management Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 88.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 106,100 shares of the biopharmaceutical company's stock after acquiring...

Varma Mutual Pension Insurance Co Boosts Stock Holdings in Bristol Myers Squibb Company $BMY

Varma Mutual Pension Insurance Co raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 353,026 shares of the biopharmac...

Seizert Capital Partners LLC Acquires 38,725 Shares of Bristol Myers Squibb Company $BMY

Seizert Capital Partners LLC lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F...

Bristol Myers Squibb Launches Won't Lose Media Campaign Ahead of FIFA World Cup 2026

Bristol Myers Squibb (NYSE: BMY) today announced the launch of Wont Lose, a new campaign debuting ahead of the FIFA World Cup 2026. Leveraging a major cultural and global moment, the Wont Lose...

CELG
Celgene Corporation

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest CELG News

CELGCelgene Corporation